IP Basics

World Intellectual Property Day

On 26th April 2012, we wish all readers happy and innovative “World IP Day”. Keeping the spirit of “visionary innovators” IIPTA has conducted series of IP workshops across various pharmaceutical and biotechnology colleges in India. Main aim of the workshop was to make students – the future innovators aware about intellectual property.   [...]

By |2017-09-07T13:08:45+05:30April 26th, 2012|IP Basics, International|0 Comments

Why India is lacking back in Patent Filing ?

Filing of patent applications under WIPO's Patent Cooperation Treaty enables companies to secure patent protection in various countries. It is a measure for knowledge-based economy and a barometer to judge the spread of innovation-based companies in each country. The international patent filings under the WIPO-administered Patent Cooperation Treaty (PCT) reached 1,81,900 applications in the [...]

By |2017-09-07T13:06:44+05:30March 14th, 2012|IP Basics|0 Comments

Compulsory Licensing to NATCO

Overview:The Controller General of Patents, Designs and Trade Marks has given a compulsory license to Hyderabad based Natco a local drug maker to manufacture and sell its generic version of German multinational Bayer’s patent-protected cancer medicine, Nexavar (Sorafenib tosylate), at about 30 times lower than charged by its Bayer Corporation. Detailed Analysis: On Monday [...]

By |2017-09-07T13:05:36+05:30March 14th, 2012|IP Basics, International|0 Comments

President Inaugurates Innovation Awards

The President of India, Smt. Pratibha Devisingh Patil presented the 6th National Grassroots Innovations Awards, and also inaugurated the Exhibition of Innovations at the President’s Estate in New Delhi today. The award function was organized by the National Innovation Foundation-India (NIF). These awards are presented to grassroots innovators and outstanding traditional knowledge holders. The [...]

By |2017-09-07T13:05:04+05:30March 9th, 2012|IP Basics, Innovation|0 Comments

Novartis last shot to protect its anti cancer drug “Glivec”

In 2006 Novartis had sued Indian Government for not granting patent to its anti cancer drug Imatinib selling under brand name ” Glivec“. It also challenged the constitutional validity of section 3 d of Indian Patent Act 1970 which says new forms including esters, ethers, acids or other derivatives of known substance are not [...]

By |2017-09-07T13:04:29+05:30March 5th, 2012|IP Basics, International|0 Comments
Go to Top